Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Spectrum Pharma Inc (SPPI)

Spectrum Pharma Inc (SPPI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 158,477
  • Shares Outstanding, K 180,087
  • Annual Sales, $ 0 K
  • Annual Income, $ -158,630 K
  • 60-Month Beta 2.24
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.86
Trade SPPI with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.88
  • Most Recent Earnings -0.09 on 05/12/22
  • Next Earnings Date 08/11/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend 0.150 on 12/18/12
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 130.60% ( -15.40%)
  • Historical Volatility 69.13%
  • IV Percentile 53%
  • IV Rank 12.83%
  • IV High 591.26% on 06/16/22
  • IV Low 62.78% on 09/01/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 834
  • Volume Avg (30-Day) 443
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 17,060
  • Open Int (30-Day) 16,206

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.16
  • Number of Estimates 3
  • High Estimate -0.13
  • Low Estimate -0.18
  • Prior Year -0.32
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6857 +28.34%
on 05/27/22
0.9690 -9.18%
on 06/24/22
+0.1704 (+24.01%)
since 05/24/22
3-Month
0.6850 +28.47%
on 05/24/22
1.4400 -38.89%
on 04/05/22
-0.4700 (-34.81%)
since 03/24/22
52-Week
0.6000 +46.67%
on 01/27/22
4.0800 -78.43%
on 06/25/21
-3.1300 (-78.05%)
since 06/24/21

Most Recent Stories

More News
Spectrum Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in two upcoming investor conferences:...

SPPI : 0.8800 (-1.18%)
Spectrum Pharmaceuticals to Present Data at 2022 ASCO Highlighting the Potential Predictive Capabilities of ctDNA as a Biomarker for Poziotinib Treatment Response

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced additional exploratory data for poziotinib in non-small cell lung...

SPPI : 0.8800 (-1.18%)
Spectrum Pharmaceuticals to Participate in H.C. Wainwright Global Investment Conference

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the upcoming H.C. Wainwright...

SPPI : 0.8800 (-1.18%)
Spectrum Pharmaceuticals (SPPI) Q1 2022 Earnings Call Transcript

SPPI earnings call for the period ending March 31, 2022.

SPPI : 0.8800 (-1.18%)
Spectrum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended March 31,...

SPPI : 0.8800 (-1.18%)
Spectrum Pharmaceuticals Appoints Nora E. Brennan as Chief Financial Officer

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Nora Brennan as Chief Financial Officer effective...

SPPI : 0.8800 (-1.18%)
Spectrum Pharmaceuticals to Report First Quarter 2022 Financial Results and Provide Corporate Update

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the first quarter 2022...

SPPI : 0.8800 (-1.18%)
Spectrum Pharmaceuticals Appoints Brittany K. Bradrick to Board of Directors

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Brittany Bradrick to its Board of Directors....

SPPI : 0.8800 (-1.18%)
Spectrum Pharmaceuticals Announces FDA Acceptance of BLA Resubmission for Eflapegrastim

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the resubmitted Biologics License Application (BLA) for eflapegrastim...

SPPI : 0.8800 (-1.18%)
Spectrum Pharmaceuticals Announces Poster Presentation at the Upcoming AACR Annual Meeting

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced abstract acceptance with a poster presentation at the upcoming American...

SPPI : 0.8800 (-1.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Spectrum Pharmaceuticals, Inc. is opportunistically acquiring and advancing a diversified portfolio of oncology drug candidates that meet critical health challenges for which there are few other treatment options. Spectrum's expertise lies in identifying undervalued drugs with demonstrated safety and...

See More

Key Turning Points

3rd Resistance Point 1.0417
2nd Resistance Point 1.0053
1st Resistance Point 0.9427
Last Price 0.8800
1st Support Level 0.8437
2nd Support Level 0.8073
3rd Support Level 0.7447

See More

52-Week High 4.0800
Fibonacci 61.8% 2.7506
Fibonacci 50% 2.3400
Fibonacci 38.2% 1.9294
Last Price 0.8800
52-Week Low 0.6000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar